GO:0008502 melatonin receptor activity: Mechanism, Genes and Research Methods
Research-grade guide for scientists and biopharma professionals
Key Takeaways
• GO:0008502 melatonin receptor activity describes the molecular function of combining with melatonin (N-acetyl-5-methoxytryptamine) to initiate a change in cell activity.
• The two canonical melatonin receptors are MT1 (MTNR1A) and MT2 (MTNR1B), both G protein-coupled receptors that signal through Gi/o proteins to inhibit cAMP and modulate downstream pathways.
• Melatonin receptor signaling regulates circadian rhythm, sleep, neuroprotection, and has been implicated in cancer, endometriosis, and metabolic disorders.
• Structural studies have revealed the ligand-binding pocket and conformational changes of melatonin receptors, enabling rational drug design.
• Melatonin receptor ligands are being developed as therapeutics for neuroprotection, glioblastoma, and epilepsy, with some showing in vivo activity.
• CRISPR-based knockout, point mutation, and knock-in models are essential to dissect the causal roles of MTNR1A and MTNR1B in physiology and disease.
Description
Melatonin receptor activity (GO:0008502) is a molecular function defined as the binding of melatonin, N-acetyl-5-methoxytryptamine, to a receptor to initiate a change in cell activity. Melatonin is a neuroendocrine substance that stimulates the aggregation of melanosomes in melanophores, thus lightening the skin, but its receptors are widely distributed and mediate diverse physiological effects. This GO term is critical for understanding how melatonin signals at the cellular level, particularly through the two high-affinity G protein-coupled receptors MT1 and MT2. Researchers studying circadian biology, neuroprotection, and cancer increasingly focus on melatonin receptor activity because it represents a druggable interface for modulating these processes. The availability of structural and pharmacological data has accelerated the development of selective ligands and genetic models to probe receptor function.
melatonin receptor activity At A Glance
| GO ID | GO:0008502 |
|---|---|
| GO term | melatonin receptor activity |
| Ontology | molecular_function |
| Synonym | none |
| Major function | Binding of melatonin to initiate intracellular signaling, typically via Gi/o-coupled GPCRs |
| Major receptors | MT1 (MTNR1A) and MT2 (MTNR1B) |
| Endogenous ligand | Melatonin (N-acetyl-5-methoxytryptamine) |
| Signaling pathway | Inhibition of adenylyl cyclase, modulation of MAPK, and other pathways |
| Tissue distribution | Brain (suprachiasmatic nucleus, retina), peripheral tissues including endometrium, immune cells |
What Is GO:0008502?
In our own words, GO:0008502 melatonin receptor activity refers to the function of a receptor protein that specifically binds melatonin and, upon binding, triggers intracellular signaling events that alter cell behavior. This activity is typically mediated by G protein-coupled receptors that couple to Gi/o proteins, leading to inhibition of adenylyl cyclase and changes in second messenger levels. The definition emphasizes both the ligand (melatonin) and the functional consequence (initiation of a change in cell activity), distinguishing it from simple melatonin binding proteins that do not signal.
Why Is melatonin receptor activity Important in Cell Biology?
Melatonin receptor activity is important because it mediates the pleiotropic effects of melatonin, a hormone that regulates circadian rhythms, sleep, immune function, and neuroprotection. Dysregulation of melatonin signaling has been linked to sleep disorders, cancer, endometriosis, and neurodegenerative diseases. Understanding this molecular function at the structural and pharmacological level enables the design of drugs that can selectively target MT1 or MT2 for therapeutic benefit. Moreover, genetic models of receptor activity are crucial for establishing causality in these disease contexts.
• Regulates circadian rhythm and sleep-wake cycles through MT1 and MT2 in the suprachiasmatic nucleus.
• Mediates neuroprotective effects of melatonin in models of Alzheimer's and Parkinson's diseases.
• Influences cancer cell proliferation and apoptosis, with implications for glioblastoma and breast cancer.
• Plays a role in endometrial physiology and endometriosis pathogenesis.
• Modulates immune responses and inflammatory pathways.
• Serves as a target for anticonvulsant and analgesic drug development.
• Structural insights into melatonin receptors facilitate rational drug design.
• Genetic variation in MTNR1B is associated with type 2 diabetes risk.
• Melatonin receptor agonists and antagonists are used experimentally to dissect receptor-specific functions.
• CRISPR-based editing of MTNR1A/MTNR1B provides causal models for receptor activity in disease.
Molecular Mechanism of melatonin receptor activity
Melatonin binding and receptor activation
In simple terms: Melatonin fits into a pocket on the receptor, like a key in a lock, and turns the receptor on.
Melatonin binds to the orthosteric pocket of MT1 and MT2 receptors, which are class A G protein-coupled receptors. Structural studies have revealed that melatonin occupies a deep pocket formed by transmembrane helices, and binding induces conformational changes that propagate to the intracellular side to facilitate G protein coupling. The binding affinity is in the low nanomolar range for both receptors.
G protein coupling and second messenger modulation
In simple terms: Once activated, the receptor talks to G proteins inside the cell, which then reduce a messenger molecule called cAMP.
Activated melatonin receptors primarily couple to Gi/o proteins, leading to inhibition of adenylyl cyclase and a decrease in intracellular cAMP levels. This reduction in cAMP modulates downstream effectors such as protein kinase A and cyclic nucleotide-gated channels. Additionally, melatonin receptors can activate other pathways including MAPK/ERK and PI3K/Akt, depending on cell context.
Receptor dimerization and signaling bias
In simple terms: Receptors can pair up, and different pairings can change how they signal.
MT1 and MT2 receptors can form homodimers and heterodimers, which may influence ligand binding and signaling properties. Heterodimerization of MT1 and MT2 has been reported to alter pharmacological profiles and may contribute to tissue-specific responses. Biased agonism at these receptors is an area of active investigation, with some ligands preferentially activating certain pathways.
Regulation by GPR50 and other interacting proteins
In simple terms: Other proteins can bind to melatonin receptors and change their activity.
The melatonin-related orphan receptor GPR50 can heterodimerize with MT1 and inhibit its function, as shown by structural and biochemical studies. This interaction provides a layer of regulation for melatonin receptor activity. Other interacting proteins, such as beta-arrestins, mediate receptor desensitization and internalization.
Key Genes Involved in GO:0008502 melatonin receptor activity
The following genes encode proteins that are directly involved in melatonin receptor activity or its regulation, based on published literature.
| Gene | Major Role | Research Relevance |
|---|---|---|
| MTNR1A | Encodes MT1 melatonin receptor, mediates Gi/o-coupled signaling | Target for sleep, circadian, and cancer studies |
| MTNR1B | Encodes MT2 melatonin receptor, mediates Gi/o-coupled signaling | Associated with type 2 diabetes and circadian regulation |
| GPR50 | Melatonin-related orphan receptor, modulates MT1 function | Regulator of melatonin signaling; structural studies |
| GNAI1 | Gi/o alpha subunit, couples to melatonin receptors | Downstream effector of receptor activation |
| GNAI2 | Gi/o alpha subunit, couples to melatonin receptors | Downstream effector of receptor activation |
| GNAI3 | Gi/o alpha subunit, couples to melatonin receptors | Downstream effector of receptor activation |
| ARRB1 | Beta-arrestin 1, mediates receptor desensitization | Regulates melatonin receptor internalization |
| ARRB2 | Beta-arrestin 2, mediates receptor desensitization | Regulates melatonin receptor internalization |
| ADCY1 | Adenylyl cyclase, inhibited by melatonin receptor signaling | Second messenger pathway |
| PRKACA | cAMP-dependent protein kinase, downstream of cAMP changes | Mediates cellular effects |
| MAPK1 | ERK2, activated by melatonin receptor signaling | Proliferation and survival pathways |
| MAPK3 | ERK1, activated by melatonin receptor signaling | Proliferation and survival pathways |
| AKT1 | PI3K/Akt pathway component, modulated by melatonin | Cell survival and metabolism |
| MTNR1A (variant) | Polymorphisms affecting receptor function | Genetic association studies |
| MTNR1B (variant) | Polymorphisms linked to diabetes risk | Genetic association studies |
| GPR50 (variant) | Mutations affecting MT1 modulation | Genetic studies of melatonin-related disorders |
How Is melatonin receptor activity Regulated?
Melatonin receptor activity is regulated at multiple levels. Receptor expression levels are controlled by circadian and tissue-specific transcription factors. Post-translational modifications, such as phosphorylation by GRKs, promote beta-arrestin recruitment and desensitization. Heterodimerization with GPR50 inhibits MT1 signaling. Additionally, the availability of melatonin, which is synthesized rhythmically, determines the extent of receptor activation. Downstream, cAMP levels and MAPK pathways are modulated by receptor activity, creating feedback loops.
melatonin receptor activity and Human Disease
| Gene | Disease / Biology | Potential Experimental Model |
|---|---|---|
| MTNR1A | Cancer (glioblastoma), circadian disorders | Knockout mice, cancer cell lines with MTNR1A KO |
| MTNR1B | Type 2 diabetes, cancer | Knockout mice, pancreatic beta cell lines with MTNR1B KO |
| GPR50 | Melatonin-related disorders, psychiatric conditions | Knockout mice, heterologous expression systems |
| MTNR1A/MTNR1B | Endometriosis | Endometrial cell lines with receptor knockdown |
| MTNR1A/MTNR1B | Neurodegeneration | Neuronal cell lines with receptor KO or overexpression |
Melatonin receptors in cancer
Melatonin receptor activity has been implicated in cancer biology. In glioblastoma, MT1 and MT2 receptors are expressed, and melatonin receptor ligands have shown in vivo activity against glioblastoma in preclinical models. Melatonin's antiproliferative and pro-apoptotic effects in cancer cells are partly mediated through MT1 and MT2. Targeting melatonin receptors is being explored as a therapeutic strategy in various cancers.
Melatonin receptors in endometriosis
Melatonin receptor expression and activity have been studied in endometrial tissue and endometriosis. Mosher et al. (2019) reported that melatonin activity and receptor expression are altered in endometriotic tissue compared to normal endometrium, suggesting a role for melatonin signaling in the pathogenesis of endometriosis. This opens avenues for receptor-targeted interventions.
Melatonin receptors in neuroprotection and neurodegeneration
Melatonin receptor activity is a target for neuroprotection. Activation of MT1 and MT2 receptors has been shown to protect neurons in models of Alzheimer's and Parkinson's diseases, potentially through antioxidant and anti-inflammatory mechanisms. Selective melatonin receptor agonists are being developed as neuroprotective agents.
Melatonin receptors in epilepsy and seizures
Melatonin has anticonvulsant activity in animal models, but the role of specific receptors is complex. Mosińska et al. (2016) found that melatonin, but not the melatonin receptor agonists Neu-P11 and Neu-P67, exhibited anticonvulsant activity in mice, suggesting that melatonin's effects may not be solely mediated by MT1/MT2. This highlights the need for further research on receptor-specific contributions.
From melatonin receptor activity-Related Genes to Experimental Models
| Research Question | Suitable Model |
|---|---|
| Does MT1 receptor activity mediate neuroprotection? | MTNR1A knockout mice or neuronal cell lines with CRISPR KO |
| What is the role of MT2 in glucose homeostasis? | MTNR1B knockout mice or pancreatic beta cell lines with KO |
| How does a specific point mutation affect ligand binding? | Knock-in mice or cell lines expressing mutant MTNR1A/MTNR1B |
| Can a tagged receptor be used to track localization? | Knock-in of fluorescent tag (e.g., GFP) into MTNR1A locus |
| Does overexpression of MT1 enhance melatonin signaling? | Stable cell lines overexpressing MTNR1A |
| What are the downstream targets of receptor activation? | CRISPR knockout of receptors followed by RNA-seq |
How to Study the melatonin receptor activity Process
| Method | What It Measures | Typical Application |
|---|---|---|
| Radioligand binding | Receptor affinity and density | Characterizing MT1/MT2 ligands |
| cAMP assay | Gi/o-mediated inhibition of adenylyl cyclase | Functional screening of agonists/antagonists |
| CRISPR knockout | Loss of receptor function | Causal studies in cell lines and mice |
| Site-directed mutagenesis | Effect of point mutations on binding | Mapping ligand-binding pocket |
| RNA-seq | Transcriptional changes upon receptor activation | Identifying downstream pathways |
| Cryo-EM | Receptor structure and conformational dynamics | Structure-based drug design |
| Behavioral assays | Circadian and sleep parameters | Evaluating receptor agonists in vivo |
Ligand binding assays
Radioligand binding assays using 2-[125I]iodomelatonin are standard to measure melatonin receptor activity and affinity. These assays can be performed on membrane preparations from cells or tissues expressing MT1/MT2. They allow determination of Kd and Bmax, and competition assays with unlabeled ligands.
Second messenger assays
Functional assays measuring cAMP levels (e.g., cAMP-Glo, FRET-based sensors) are used to assess receptor activation, as melatonin receptors inhibit adenylyl cyclase. Other assays include GTPγS binding and reporter gene assays driven by cAMP response elements.
Genetic manipulation and CRISPR screens
CRISPR/Cas9 knockout of MTNR1A or MTNR1B in cell lines or animal models allows causal testing of receptor function. Point mutations can be introduced to study ligand binding residues. Knock-in of tags enables imaging. Library screening can identify modifiers of melatonin signaling.
Structural biology and computational modeling
Cryo-EM and X-ray crystallography have provided structures of melatonin receptors, revealing the binding pocket and conformational changes. Molecular dynamics simulations complement these studies to understand ligand-receptor interactions and guide drug design.
How CRISPR Can Be Used to Study GO:0008502 melatonin receptor activity
Knockout
CRISPR/Cas9-mediated knockout of MTNR1A or MTNR1B is used to eliminate receptor activity and study its role in cellular processes and disease models. For example, knockout of MTNR1A in cancer cell lines can reveal whether melatonin's antiproliferative effects are receptor-dependent.
Point Mutation
Point mutations can be introduced into MTNR1A or MTNR1B to study the impact of specific amino acid residues on ligand binding and signaling. This is particularly useful for validating structural models and understanding receptor polymorphisms associated with disease.
Knock-in
Knock-in of reporter tags (e.g., GFP, luciferase) into the endogenous MTNR1A or MTNR1B locus allows real-time monitoring of receptor expression and localization. Knock-in of disease-associated mutations can create isogenic models for studying pathogenesis.
Overexpression
Overexpression of MTNR1A or MTNR1B in cell lines is used to amplify receptor signaling for biochemical assays and to study downstream effects. This approach is valuable for drug screening and for understanding signaling bias.
How EDITGENE Supports melatonin receptor activity Research
Researchers studying melatonin receptor activity-related genes often need to determine whether a candidate gene is causally involved in a specific biological process or disease. EDITGENE provides a comprehensive suite of CRISPR-based services to enable such investigations, from gene knockout to precise point mutations and knock-in models.
Contact EDITGENE today to design your custom CRISPR model for melatonin receptor activity research.
Frequently Asked Questions About melatonin receptor activity
What is melatonin receptor activity?
Melatonin receptor activity (GO:0008502) is the molecular function of binding melatonin to initiate a change in cell activity, typically through G protein-coupled receptors MT1 and MT2.
What genes are involved in melatonin receptor activity?
The primary genes are MTNR1A (MT1) and MTNR1B (MT2), which encode the two canonical melatonin receptors. GPR50 is a related orphan receptor that modulates MT1 activity.
What is the GO ID for melatonin receptor activity?
The Gene Ontology ID for melatonin receptor activity is GO:0008502.
How does melatonin receptor signaling work?
Melatonin binds to MT1 or MT2, which couple to Gi/o proteins to inhibit adenylyl cyclase and reduce cAMP, thereby altering downstream pathways.
What diseases are associated with melatonin receptor activity?
Melatonin receptor activity has been implicated in cancer, endometriosis, neurodegenerative diseases, type 2 diabetes, and circadian rhythm disorders.
What are the research methods to study melatonin receptor activity?
Common methods include radioligand binding assays, cAMP assays, CRISPR knockout, site-directed mutagenesis, RNA-seq, and structural biology techniques like cryo-EM.
Can CRISPR be used to study melatonin receptors?
Yes, CRISPR/Cas9 can generate knockout, point mutation, and knock-in models of MTNR1A and MTNR1B to study their function in health and disease.
What is the structure of melatonin receptors?
MT1 and MT2 are class A GPCRs with a seven-transmembrane architecture. Recent cryo-EM structures have revealed the melatonin-binding pocket and conformational changes.
Are there drugs targeting melatonin receptors?
Yes, melatonin receptor agonists like ramelteon and agomelatine are used clinically, and new ligands are being developed for neuroprotection and cancer.
What is the role of GPR50 in melatonin signaling?
GPR50 is an orphan receptor that heterodimerizes with MT1 and inhibits its function, acting as a negative regulator of melatonin signaling.
Conclusion
Melatonin receptor activity (GO:0008502) is a fundamental molecular function that mediates the diverse actions of melatonin in physiology and disease. The two canonical receptors, MT1 and MT2, are well-characterized GPCRs with important roles in circadian regulation, neuroprotection, cancer, and metabolic disorders. Advances in structural biology and CRISPR-based genetic models continue to unravel the complexities of melatonin signaling. Targeting these receptors holds promise for therapeutic development, and EDITGENE provides the tools to accelerate such research.
References
- 1. Okamoto HH et al.. 2024. Melatonin receptor structure and signaling.. J Pineal Res 76(3):e12952 PMID: 38587234
- 2. Mosher AA et al.. 2019. Melatonin activity and receptor expression in endometrial tissue and endometriosis.. Hum Reprod 34(7):1215-1224 PMID: 31211323
- 3. Liu J et al.. 2016. MT1 and MT2 Melatonin Receptors: A Therapeutic Perspective.. Annu Rev Pharmacol Toxicol 56:361-83 PMID: 26514204
- 4. Wongprayoon P et al.. 2021. Melatonin Receptor as a Drug Target for Neuroprotection.. Curr Mol Pharmacol 14(2):150-164 PMID: 32316905
- 5. Mosińska P et al.. 2016. Anticonvulsant activity of melatonin, but not melatonin receptor agonists Neu-P11 and Neu-P67, in mice.. Behav Brain Res 307:199-207 PMID: 27016427
- 6. Bedini A et al.. 2026. N-Acylaminoethyltetrahydroquinolines: A new class of melatonin receptor ligands with in vivo activity on glioblastoma.. Eur J Med Chem 303:118445 PMID: 41389411
- 7. Mahmood D. 2019. Pleiotropic Effects of Melatonin.. Drug Res (Stuttg) 69(2):65-74 PMID: 30060265
- 8. Shin J et al.. 2026. Structure of the melatonin-related orphan receptor, GPR50.. Mol Cells 49(4):100331 PMID: 41666959
